Active — Not RecruitingNot Applicable

Hepatic Resection for Metastatic Pancreatic Cancer

United States18 participantsStarted 2018-05-18

Plain-language summary

The purpose of this study is to demonstrate the feasibility of an aggressive multimodal approach among patients with stage IV pancreatic cancer (PAC) with isolated, low-volume hepatic metastasis (LVHM). We will evaluate and describe the surgical and overall outcomes of an initial cohort of subjects who undergo pancreatectomy and hepatic resection/ablation for PAC with LVHM. The end of study results will be reviewed by the Hepatiobiliary Multidisciplinary Conference (HDMC) and Surgery Audit Committee (SAC) to determine the appropriateness of adding this treatment arm for patients with oligometastatic metastatic pancreatic cancer.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subject must be at least 18 years of age and at least the minimum Age of Majority according to applicable State or Country Law * Subject is a surgical candidate, (i.e., is able to undergo general anesthesia and surgical resection for diagnosis of cancer) * The Hepatobiliary Multidisciplinary Committee (HDMC) must approved of this intervention. * Insurance pre-authorization must be received unless the subject decides to pay out of pocket.. * Subject has been informed of the study procedures and the treatment and has signed an informed consent form * less than or equal to 3 liver lesions Exclusion Criteria: * Subject is not a suitable candidate for surgical intervention * The Hepatobiliary Multidisciplinary Committee (HDMC) disapproves of this intervention. * Insurance will not cover the procedure or subject not willing to pay out of pocket. * Pregnant women * Non-English speaking Subjects

What they're measuring

90-day mortality

Timeframe: 90 days postoperatively

Disease Progression

Timeframe: up to 1 year postoperatively

Overall Survival

Timeframe: up to 1 year postoperatively

Trial details

NCT IDNCT02892305

SponsorDuke University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-05-17